New company to invest up to EUR 19 million in life science startups

SmiLe Incubator:   SmiLe Incubator is now launching SmiLe Inject Capital AB, the first angel investment company in Sweden that focuses solely on promising early-stage life science companies. The financing is provided by experienced business angels along with the state-owned venture capital company Saminvest.

Through INJECT, private investors are being offered the opportunity for the first time to benefit from SmiLe’s comprehensive life science expertise, international networks and unique insights into early- stage life science companies.

Investments will be made in companies that have participated in SmiLe’s incubator program for at least six months, or an equivalent program at a recognized innovation partner in Southern Sweden.

The aim is to invest EUR 3,9 million (SEK 40 million) in 10-15 promising life science companies over two years. There is also an opportunity for follow-on investments totaling EUR 15 million (SEK 150 million) through business angels and Saminvest’s Annexstruktur.

“I am incredibly proud and pleased that together with experienced business angels and Saminvest we can now launch SmiLe Inject Capital. All successful incubator environments worldwide are associated with capital and the fact that we can now offer innovative life science companies in Southern Sweden access to venture capital is an important milestone for SmiLe. This step also enables us to contribute to the development of more Swedish innovations that can stay in Sweden, which is crucial for us to maintain our international competitiveness,” says Ebba Fåhraeus, CEO of SmiLe Incubator.

The business angels in SmiLe Inject include 11 well-known Swedish investors.

The initiative will help to strengthen the financial ecosystem for life science companies in Southern Sweden, thereby accelerating commercialization of innovations in pharmaceuticals, medtech and e- health.

“We are extremely pleased that Saminvest and SmiLe are now establishing a dedicated investment company for early-stage life science companies. SmiLe Inject Capital will be an important addition to the

Swedish life science industry, where access to both capital and ownership expertise are essential for companies to achieve successful development,” says Peder Hasslev, CEO of Saminvest AB.

SmiLe Incubator

4 inspiring CEOs, 4 professional journeys

SmiLe Incubator:  Sharing expertise and knowledge is an important part of being professional in the SmiLe community. And, as we are wrapping up this month’s core value focus “Professional”, we put the spotlight on four of our talented CEO’s. They all come from different backgrounds and their careers have taken them along different paths. However, they all share a passion for life science and for developing products and solutions that have an impact on peoples’ lives. In this article, they talk about their professional journeys, and share their top-3 tips for other young and aspiring entrepreneurs.

Innovative healthtech project kickstarts at SmiLe Bootcamp

SmiLe Incubator:  The seventh edition of SmiLe’s ten-week program for early companies and entrepreneurs with innovative ideas and products in healthtech, medtech and eHealth is now underway. The projects address key care-related areas such as pain, psychiatric disorders and postnatal problems. The goal is to make the projects investment-ready. The program culminates with a DemoDay on June 17.

SmiLe launches BioTech program with German BioM and Merck

SmiLe Incubator:  In collaboration with one of Europe's leading biotechnology clusters, BioM, in Germany, SmiLenow launches a new, international training program, BioTech Bootcamp. The program, which is sponsored by Merck, a global leader in pharmaceuticals and life science technology, is based on SmiLe's successful Bootcamp concept and is tailored for future entrepreneurs who want to develop and commercialize their business ideas in biotechnology.